Treatment of hypertension during the COVID-19 pandemic: questions about the blockade of the renin-angiotensin-aldosterone system
Arterial hypertension was one of the most common comorbidities associated with a high risk of death in hospitalized patients with COVID-19.Patients with hypertension are routinely and according to standards treated with angiotensinconverting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARB) II.ACE inhibitors or ARB II are in